LifeStance Health Group (NASDAQ:LFST) Stock Price Expected to Rise, KeyCorp Analyst Says

LifeStance Health Group (NASDAQ:LFST) had its price target raised by equities researchers at KeyCorp from $8.00 to $9.00 in a research note issued to investors on Thursday,Benzinga reports. The firm presently has an “overweight” rating on the stock. KeyCorp’s price objective would indicate a potential upside of 26.85% from the company’s previous close.

A number of other research firms also recently issued reports on LFST. Wall Street Zen raised shares of LifeStance Health Group from a “hold” rating to a “buy” rating in a report on Sunday, February 8th. BMO Capital Markets started coverage on LifeStance Health Group in a research report on Thursday, November 13th. They set an “outperform” rating and a $8.00 price target on the stock. UBS Group upped their price objective on LifeStance Health Group from $9.00 to $10.00 and gave the stock a “buy” rating in a report on Friday, November 7th. Barclays assumed coverage on LifeStance Health Group in a research report on Tuesday, December 9th. They set an “overweight” rating and a $8.00 price objective on the stock. Finally, Weiss Ratings reissued a “sell (d-)” rating on shares of LifeStance Health Group in a report on Monday, December 29th. One equities research analyst has rated the stock with a Strong Buy rating, six have given a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and an average target price of $9.00.

LifeStance Health Group Price Performance

Shares of NASDAQ LFST traded down $0.32 during midday trading on Thursday, hitting $7.10. 2,944,276 shares of the company’s stock were exchanged, compared to its average volume of 1,795,452. The company has a current ratio of 1.58, a quick ratio of 1.58 and a debt-to-equity ratio of 0.18. The business’s fifty day moving average price is $7.12 and its two-hundred day moving average price is $6.18. The company has a market cap of $2.76 billion, a price-to-earnings ratio of -233.37 and a beta of 1.12. LifeStance Health Group has a 12-month low of $3.74 and a 12-month high of $8.30.

LifeStance Health Group (NASDAQ:LFST) last announced its earnings results on Wednesday, February 25th. The company reported $0.03 earnings per share for the quarter, missing analysts’ consensus estimates of $0.05 by ($0.02). LifeStance Health Group had a negative net margin of 0.67% and a negative return on equity of 0.62%. The company had revenue of $382.20 million during the quarter, compared to analysts’ expectations of $378.51 million. During the same period in the prior year, the business earned ($0.01) earnings per share. The company’s revenue for the quarter was up 17.4% compared to the same quarter last year. As a group, research analysts forecast that LifeStance Health Group will post -0.18 EPS for the current fiscal year.

LifeStance Health Group announced that its Board of Directors has authorized a stock repurchase plan on Wednesday, February 25th that authorizes the company to buyback $100.00 million in shares. This buyback authorization authorizes the company to purchase up to 3.6% of its stock through open market purchases. Stock buyback plans are often a sign that the company’s board of directors believes its stock is undervalued.

Insider Activity at LifeStance Health Group

In other LifeStance Health Group news, Director Robert Bessler sold 119,942 shares of the firm’s stock in a transaction on Friday, December 19th. The shares were sold at an average price of $7.04, for a total value of $844,391.68. Following the sale, the director owned 1,318,983 shares of the company’s stock, valued at $9,285,640.32. This trade represents a 8.34% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, insider Ann Varanakis sold 50,000 shares of the firm’s stock in a transaction dated Wednesday, December 17th. The stock was sold at an average price of $6.90, for a total value of $345,000.00. Following the completion of the sale, the insider directly owned 315,610 shares in the company, valued at $2,177,709. The trade was a 13.68% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Over the last 90 days, insiders have sold 270,086 shares of company stock worth $1,891,264. 3.20% of the stock is owned by corporate insiders.

Institutional Trading of LifeStance Health Group

Several large investors have recently added to or reduced their stakes in the stock. Larson Financial Group LLC raised its holdings in LifeStance Health Group by 19,952.6% in the 4th quarter. Larson Financial Group LLC now owns 3,810 shares of the company’s stock worth $27,000 after purchasing an additional 3,791 shares in the last quarter. Bayesian Capital Management LP bought a new stake in shares of LifeStance Health Group during the 2nd quarter valued at about $52,000. Krane Funds Advisors LLC purchased a new position in shares of LifeStance Health Group during the fourth quarter valued at about $71,000. Vanguard Personalized Indexing Management LLC bought a new position in LifeStance Health Group in the third quarter worth about $72,000. Finally, Cibc World Markets Corp bought a new position in LifeStance Health Group in the fourth quarter worth about $77,000. Institutional investors own 85.50% of the company’s stock.

More LifeStance Health Group News

Here are the key news stories impacting LifeStance Health Group this week:

• Positive Sentiment: Q4 revenue and profitability improved materially — revenue rose 17% to $382.2M, full‑year revenue grew 14%, Q4 net income was $11.7M and adjusted EBITDA jumped 49%, signalling stronger demand and operating leverage. LifeStance Reports Fourth Quarter and Full Year 2025 Results
• Positive Sentiment: Board approved a $100M share repurchase program (up to ~3.6% of outstanding shares), which supports buyback-driven capital return and signals management confidence. LifeStance Reports Fourth Quarter and Full Year 2025 Results
• Neutral Sentiment: Company provided 2026 guidance: revenue $1.615B–$1.655B and adjusted EBITDA $185M–$205M. Guidance is growth‑oriented but investors will monitor execution vs. the midpoint. LifeStance Reports Fourth Quarter and Full Year 2025 Results
• Neutral Sentiment: Some outlets emphasize that revenue and other metrics beat estimates (revenue beat consensus), while EPS coverage is mixed depending on the comparator — this creates divergent analyst/tone impact. LifeStance Health Group (NASDAQ:LFST) Posts Better-Than-Expected Sales In Q4 CY2025, Stock Jumps 12.7%
• Negative Sentiment: Reported EPS of $0.03 missed the consensus ~$0.05 (market‑reported miss), which likely disappointed short‑term earnings expectations despite revenue strength. LifeStance Health Group, Inc. Q4 2025 Earnings Call Transcript
• Negative Sentiment: Selling stockholders launched a secondary offering of 25M shares (company not selling/receiving proceeds), creating immediate supply overhang and downward pressure on the float. LifeStance Health Group Announces Launch of Secondary Public Offering
• Negative Sentiment: Recent insider selling and some large institutional reductions noted in public data, which can amplify selling pressure and investor caution. QuiverQuant summary of Q4 results and insider activity

About LifeStance Health Group

LifeStance Health Group (NASDAQ:LFST) is a leading provider of outpatient mental health services in the United States. Headquartered in New York City, the company operates a growing network of clinics that deliver integrated, patient-centered psychological and psychiatric care. LifeStance’s mission is to expand access to high-quality mental health treatment by combining evidence-based therapy modalities with personalized treatment plans.

The company’s service offerings include individual, family, and group psychotherapy, psychiatric medication management, psychological assessment, and telehealth services.